Gilead Sciences Inc (GILD) FY2025Q4 Earning Prediction
Gilead Sciences Inc (GILD) is set to release its FY2025Q4 earnings performance on 02/10 16:02:00 ET in After Hours trading. Consensus forecasts predict a revenue of 7.57B and an earnings per share (EPS) of 1.83 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
Gilead is anticipated to miss revenue expectations due to pricing pressures and mixed clinical outcomes, though cost controls may stabilize EPS.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Key Fact Data Impacts:
- Drug Price Reductions:
Gilead agreed to U.S. government-mandated price cuts under the "most-favored-nation" framework, which directly pressures revenue for HIV, hepatitis, and COVID-19 therapies (Veklury, Epclusa). Medicaid discounts and parity pricing for future drugs amplify this risk.
Impact: Likely below-consensus pricing power for key revenue drivers like Biktarvy and Descovy.
- Clinical/Trial Data:
Positive Trodelvy Data: Phase 3 ASCENT-04 showed a 35% reduction in PFS risk for Trodelvy + Keytruda in metastatic TNBC, supporting near-term revenue upside. However, Trodelvy’s recent failure in ASCENT-07 (HR+/HER2
breast cancer) limits broader growth potential.
HIV Pipeline Strength: ARTISTRY-2 trial success (BIC/LEN non-inferior to Biktarvy) and UK approval of Yeytuo (lenacapavir for PrEP) signal long-term franchise durability but face delayed monetization.
- Regulatory/Competitive Risks:
Cell Therapy Pressures: Despite strong anito-cel data (96% ORR in myeloma), competitive CAR-T therapies and site access challenges persist.
STAR-221 Discontinuation: Phase 3 gastric cancer trial failure for domvanalimab/zimberelimab weakens oncology diversification efforts.
- Operational Risks:
- Veklury Recall: Voluntary recall of one lot due to glass particles may marginally impact COVID-19 drug sales and raise near-term scrutiny.
Tactical Strategy Recommendations
- Short-Term Put Options: Target $130-$135 strikes ahead of earnings to hedge against revenue miss.
- Pairs Trade: Long GILD/short ARCX (Arcellx) – Anito-cel success is priced into ACLX but faces execution risk for GILD’s cell therapy segment.
- Post-Earnings Swing: Buy calls if guidance reaffirms HIV growth (e.g., Yeztugo PrEP momentum) despite pricing concerns.
Rationale: High expectations (16% stock outperformance) leave minimal room for error. Drug pricing headwinds and mixed pipeline catalysts favor a cautious stance.
Earnings Surprise Analysis
GILD Transcript
GILD Slides
GILD Report
Frequently Asked Questions
What is the Gilead Sciences Inc FY2025Q4 Earnings Release Date and Time?
Gilead Sciences Inc (GILD) is scheduled to release its FY2025Q4 earnings report onFeb 10, 2026, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Gilead Sciences Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 7.57B in revenue and an EPS of 1.83 for Gilead Sciences Inc's FY2025Q4.
What Does Intellectia's AI Predict for Gilead Sciences Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a Miss forGilead Sciences Inc's FY2025Q4 earnings, with a prediction date of Feb 10, 2026. Gilead Sciences Inc Gilead is anticipated to miss revenue expectations due to pricing pressures and mixed clinical outcomes, though cost controls may stabilize EPS.
How Can I Use This Earnings Prediction to Trade GILD Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 10, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Gilead Sciences Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
